László Szilberhorn

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Clinical Practice

Particulate Matter

Polycyclic Aromatic Hydrocarbons

Top Venues

Personalized medicine

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Tanya Rajabi, László Szilberhorn, Dávid Győrbíró, Manna Tatár, Zoltán Vokó, Balázs Nagy
Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography: Comparing Hungarian Screening Protocols with the US NLST. Cancers 16 (17) (2024)
Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK. Personalized medicine (2023)
László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Balázs Nagy
Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries. Personalized medicine (2023)
Gábor Kovács, Dávid Nagy, László Szilberhorn, Tamás Zelei, Zsolt Gaál, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Balázs Nagy
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young. Personalized medicine (2023)
Balázs Nagy, Tamás Zelei, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, László Szilberhorn
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies. Personalized medicine (2023)
Rositsa Koleva-Kolarova, László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Balázs Nagy, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, Sarah Wordsworth, Apostolos Tsiachristas
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Personalized medicine (2023)
Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen P M H Rutten-van Mölken, null null
Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries. Personalized medicine (2023)
Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas
Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Personalized medicine (2023)
Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Maureen P M H Rutten-van Mölken, null null
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. PharmacoEconomics 39 (7) (2021)